R&G PharmaStudies Co., Ltd. (SHE:301333)

R&G PharmaStudies Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 22, 2026	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Market Capitalization	6,661	4,756	6,190	4,940	-	-
Market Cap Growth	41.15%	-23.17%	25.30%	-	-	-
Enterprise Value	4,955	3,124	4,564	3,498	-	-
Last Close Price	70.01	49.83	63.89	50.84	-	-
PE Ratio	43.99	33.92	38.09	43.55	-	-
Forward PE	44.73	25.30	-	-	-	-
PS Ratio	8.44	6.39	8.58	7.75	-	-
PB Ratio	3.46	2.59	3.53	3.10	-	-
P/TBV Ratio	3.66	2.75	3.58	3.14	-	-
P/FCF Ratio	111.45	35.29	35.85	45.06	-	-
P/OCF Ratio	79.49	30.73	32.15	37.87	-	-
EV/Sales Ratio	6.28	4.20	6.33	5.49	-	-
EV/EBITDA Ratio	34.02	24.26	29.69	31.68	-	-
EV/EBIT Ratio	36.42	25.81	34.81	33.97	-	-
EV/FCF Ratio	82.91	23.18	26.43	31.90	-	-
Debt / Equity Ratio	0.01	0.04	0.01	0.01	0.03	-
Debt / EBITDA Ratio	0.06	0.51	0.05	0.13	0.08	-
Debt / FCF Ratio	0.16	0.53	0.05	0.14	0.14	-
Asset Turnover	0.34	0.34	0.37	0.50	1.01	1.00
Inventory Turnover	7.33	8.04	8.33	8.36	10.43	11.18
Quick Ratio	5.72	4.73	6.20	6.25	2.35	2.32
Current Ratio	5.96	4.88	6.38	6.45	2.58	2.54
Return on Equity (ROE)	8.22%	7.90%	9.73%	11.24%	25.91%	29.07%
Return on Assets (ROA)	3.68%	3.43%	4.14%	5.03%	11.35%	11.30%
Return on Invested Capital (ROIC)	60.57%	113.70%	159.47%	104.63%	136.45%	825.80%
Return on Capital Employed (ROCE)	6.90%	6.40%	7.50%	6.40%	24.60%	26.00%
Earnings Yield	2.27%	2.95%	2.63%	2.30%	-	-
FCF Yield	0.90%	2.83%	2.79%	2.22%	-	-
Dividend Yield	0.23%	0.32%	0.31%	0.31%	-	-
Payout Ratio	10.37%	20.24%	3.58%	-	-	-
Buyback Yield / Dilution	-21.90%	-22.07%	4.95%	-14.43%	0.38%	-0.37%
Total Shareholder Return	-21.67%	-21.75%	5.26%	-14.12%	0.38%	-0.37%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.